Comparison
BPC-157 vs GHRP-6
Side-by-side of BPC-157 and GHRP-6. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
GHRP-6
First-generation hexapeptide ghrelin-receptor agonist. Pioneered the GHS-R1a pathway in the 1980s. Produces the strongest hunger response among GHRPs and a mo.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
GHRP-6
- •First-generation hexapeptide ghrelin-receptor agonist; foundational to the GHRP class
- •Strongest appetite stimulation of any synthetic GHRP at equivalent GH doses
- •Produces measurable cortisol and prolactin rise alongside the GH pulse
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Largely superseded by ipamorelin (cleaner profile) and GHRP-2 (stronger pulse) for body-composition use
- •Banned by WADA under S2; detection methods validated in accredited labs
Side-by-side
| Attribute | BPC-157 | GHRP-6 |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | Growth Hormone Releasing Peptide 6, SKF-110679, Histidyl-D-Tryptophyl-Alanyl-Tryptophyl-D-Phenylalanyl-Lysinamide |
| Half-life (hr) ↗ | 4 | 0.5 |
| Typical dose (mg) ↗ | 0.25 | 0.1 |
| Dosing frequency | daily (anecdotal protocols) | 2-3x daily |
| Routes | subcutaneous, intramuscular, oral | subcutaneous, intravenous |
| Onset (hr) | - | 0.25 |
| Peak (hr) | - | 0.5 |
| Molecular weight | - | 872.44 |
| Molecular formula | C62H98N16O22 | C46H56N12O6 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Hexapeptide agonist of GHS-R1a (ghrelin receptor). Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs, with strong central NPY/AgRP appetite signaling and modest cortisol and prolactin release. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled (research chemical) |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 137525-51-0 | 87616-84-0 |
| PubChem CID | 9941957 | 9919072 |
| Wikidata | Q4835418 | Q5519921 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
GHRP-6
Common side effects
- intense hunger
- water retention
- vivid dreams
- head pressure or flushing
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin sensitivity
Interactions
- CJC-1295: synergistic GH release; commonly co-administered(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Which Should You Take?
GHRP-6 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is growth-hormone axis, pick GHRP-6.
- → If your priority is appetite regulation, pick GHRP-6.
Edge case: If you cannot self-administer injections, BPC-157 is the only oral option in this pair.
Default choice: GHRP-6. Wider use case, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and GHRP-6?
BPC-157 and GHRP-6 differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or GHRP-6?
BPC-157 half-life is 4 hours; GHRP-6 half-life is 0.5 hours.
Can you stack BPC-157 with GHRP-6?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper